ArticleJournal of translational medicine2026
Redox-senescence function of PON1 in hepatocellular carcinoma and its non-invasive assessment using super-resolution radiomics: a multi-center study.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundRisk stratification in hepatocellular carcinoma (HCC) is limited by the lack of robust biomarkers reflecting tumor biology. The antioxidant enzyme Paraoxonase-1 (PON1) shows prognostic potential, yet its role in tumor tissues and the feasibility of non-invasive assessment remain unclear.
methodsSenescence-related pathways and prognostic candidates were screened using transcriptomic data from TCGA-LIHC and GTEx. PON1 expression was validated in multicenter cohorts through qPCR, immunohistochemistry, and Western blotting. Functional assays in PON1 knockdown and overexpression models evaluated oxidative stress, glutathione balance, mitochondrial dysfunction, and senescence markers. We developed a radiomics model based on contrast-enhanced CT scans with super-resolution reconstruction to predict tumoral PON1 expression. This radiomics signature was then integrated with clinical variables to build a combined model, which was evaluated across training, validation, test, and external cohorts.
resultsPON1 was identified as a downregulated senescence-related prognostic gene. Low PON1 expression was associated with poorer overall and progression-free survival across independent clinical cohorts. PON1 depletion increased intracellular and mitochondrial ROS, lowered the GSH/GSSG ratio, impaired mitochondrial membrane potential, and induced senescence phenotypes, while its restoration mitigated these effects. SR-enhanced radiomics improved prediction of tumoral PON1 expression across all cohorts. Integration of radiomics signatures with clinical variables further improved discrimination, achieving the highest accuracy and net clinical benefit.
conclusionPON1 downregulation contributes to oxidative stress-driven senescence and unfavorable clinical outcomes in HCC. SR-enhanced radiomics provides an accurate, non-invasive method for estimating tumoral PON1 expression, demonstrating potential value for radiogenomic profiling and preoperative risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.